MCID: ANL017
MIFTS: 48

Anal Squamous Cell Carcinoma

Categories: Gastrointestinal diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 15 73
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 50 C9161
SNOMED-CT 68 255084004
UMLS 73 C1412036

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to suppressor of tumorigenicity 3 and cervix carcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Regulation of TP53 Activity. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and colon, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.7 CDKN2A TP53
2 cervix carcinoma 30.4 CDKN2A TP53
3 squamous cell carcinoma 30.3 AKT1 CDKN2A PIK3CA TP53
4 adenocarcinoma 27.3 AKT1 APC CDKN2A MLH1 PIK3CA TP53
5 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
6 keratinizing squamous cell carcinoma 10.7 CDKN2A TP53
7 spitz nevus 10.7 CDKN2A TP53
8 bladder carcinoma in situ 10.7 CDKN2A TP53
9 bartholin's gland benign neoplasm 10.7 CDKN2A TP53
10 vulva squamous cell carcinoma 10.7 CDKN2A TP53
11 thyroid lymphoma 10.6 CDKN2A TP53
12 nasal cavity adenocarcinoma 10.6 CDKN2A TP53
13 bone squamous cell carcinoma 10.6 CDKN2A TP53
14 scrotal carcinoma 10.6 CDKN2A TP53
15 glycogen-rich clear cell breast carcinoma 10.6 CDKN2A TP53
16 gastric adenosquamous carcinoma 10.6 CDKN2A TP53
17 oral leukoplakia 10.6 CDKN2A TP53
18 anogenital venereal wart 10.6 CDKN2A TP53
19 megaesophagus 10.6 CDKN2A TP53
20 cervix uteri carcinoma in situ 10.6 CDKN2A TP53
21 schneiderian carcinoma 10.6 CDKN2A TP53
22 meningeal melanomatosis 10.6 CDKN2A TP53
23 dedifferentiated liposarcoma 10.6 CDKN2A TP53
24 oropharynx cancer 10.6 CDKN2A TP53
25 endocervical adenocarcinoma 10.6 CDKN2A TP53
26 cervix small cell carcinoma 10.6 CDKN2A TP53
27 necrotizing sialometaplasia 10.6 CDKN2A TP53
28 basaloid squamous cell carcinoma 10.5 CDKN2A TP53
29 hyperplastic polyposis syndrome 10.5 APC TP53
30 biliary tract neoplasm 10.5 CDKN2A TP53
31 inverted papilloma 10.5 CDKN2A TP53
32 mutyh-associated polyposis 10.5 APC TP53
33 optic nerve neoplasm 10.5 CDKN2A TP53
34 polyposis syndrome, hereditary mixed, 1 10.5 APC MLH1
35 recessive dystrophic epidermolysis bullosa 10.5 CDKN2A TP53
36 vulva cancer 10.5 CDKN2A TP53
37 adult hepatocellular carcinoma 10.5 PIK3CA TP53
38 richter's syndrome 10.5 MLH1 TP53
39 malignant spiradenoma 10.5 PIK3CA TP53
40 squamous cell papilloma 10.5 CDKN2A TP53
41 pre-malignant neoplasm 10.5 CDKN2A TP53
42 juvenile pilocytic astrocytoma 10.4 CDKN2A TP53
43 breast squamous cell carcinoma 10.4 PIK3CA TP53
44 barrett's adenocarcinoma 10.4 CDKN2A TP53
45 mucinous adenocarcinoma 10.4 CDKN2A MLH1
46 monophasic synovial sarcoma 10.4 MLH1 RASSF1
47 esophagus adenocarcinoma 10.4 PIK3CA TP53
48 prostate squamous cell carcinoma 10.4 PIK3CA TP53
49 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 PIK3CA TP53
50 hepatic adenomas, familial 10.3 APC RASSF1

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 8.92 MGMT MLH1 RASSF1 TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 CDKN2A PIK3CA AKT1 MGMT APC MLH1
2 homeostasis/metabolism MP:0005376 10.08 CDKN2A AKT1 MGMT APC MLH1 RASSF1
3 cellular MP:0005384 10.07 CDKN2A AKT1 APC MLH1 PIK3CA RASSF1
4 cardiovascular system MP:0005385 10.01 CDKN2A AKT1 APC PIK3CA RASSF1 TP53
5 mortality/aging MP:0010768 10.01 CDKN2A AKT1 MGMT APC MLH1 PIK3CA
6 integument MP:0010771 9.93 CDKN2A AKT1 APC MLH1 PIK3CA TP53
7 neoplasm MP:0002006 9.92 CDKN2A PIK3CA AKT1 MGMT APC MLH1
8 digestive/alimentary MP:0005381 9.91 MLH1 CDKN2A APC RASSF1 TP53
9 liver/biliary system MP:0005370 9.83 CDKN2A AKT1 APC RASSF1 TP53
10 muscle MP:0005369 9.77 CDKN2A AKT1 APC TP53 PIK3CA
11 no phenotypic analysis MP:0003012 9.65 CDKN2A MGMT APC PIK3CA TP53
12 reproductive system MP:0005389 9.63 CDKN2A AKT1 APC MLH1 PIK3CA TP53
13 respiratory system MP:0005388 9.35 MLH1 CDKN2A AKT1 MGMT TP53
14 vision/eye MP:0005391 9.02 APC MLH1 CDKN2A TP53 PIK3CA

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
5 Albumin-Bound Paclitaxel Phase 3,Phase 2
6 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antimitotic Agents Phase 3,Phase 2
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
11 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
16
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
17
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
19
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
20
Pembrolizumab Approved Phase 2 1374853-91-4
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22 Antibodies Phase 2,Phase 1
23 Immunoglobulins Phase 2,Phase 1
24 Antibodies, Monoclonal Phase 2,Phase 1
25 Central Nervous System Depressants Phase 2
26 GABA Agents Phase 2
27 Neurotransmitter Agents Phase 2
28 Tranquilizing Agents Phase 2
29 Anticonvulsants Phase 2
30 Psychotropic Drugs Phase 2
31 Antimanic Agents Phase 2
32 Antiviral Agents Phase 2
33 taxane Phase 2
34
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
35
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
36
nivolumab Approved Phase 1 946414-94-4
37
Manganese Approved, Nutraceutical Phase 1 7439-96-5 27854
38 Vaccines Phase 1
39 Antirheumatic Agents Phase 1
40 Antineoplastic Agents, Alkylating Phase 1
41
Dimenhydrinate Approved 523-87-5 441281
42
Ethanol Approved 64-17-5 702
43
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
44 Pharmaceutical Solutions

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
3 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
4 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
5 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
6 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
8 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
10 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
11 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
12 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
13 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
14 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
15 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
16 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
17 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
18 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
19 A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer Recruiting NCT02797964 Phase 1, Phase 2 SRA737
20 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
21 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
22 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
23 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
24 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2 Lymphoseek
25 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
26 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
27 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting NCT03386500 Phase 1 BMX-001
28 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
29 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
30 ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
31 Molecular Biology of Anal Cancer in HIV-Positive Patients Completed NCT00952874
32 Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? Completed NCT03469596
33 Anal Dysplasia in Patients With Inflammatory Bowel Disease Completed NCT01653054 Not Applicable
34 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
35 Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients Recruiting NCT01877135
36 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021 Not Applicable
37 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Recruiting NCT03241680 Not Applicable
38 Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men Recruiting NCT02816879 Not Applicable
39 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
40 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435 Not Applicable
41 Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561
42 Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer Withdrawn NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

41
Lymph Node, T Cells, Colon, Cervix

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 97)
# Title Authors Year
1
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
2
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
3
Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )
2018
4
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
5
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
6
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
7
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )
2018
8
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )
2018
9
Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )
2018
10
The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )
2018
11
Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )
2017
12
Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )
2017
13
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )
2017
14
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )
2017
15
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
16
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )
2017
17
Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )
2017
18
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )
2017
19
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
20
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
21
The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )
2017
22
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )
2017
23
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )
2017
24
Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )
2017
25
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )
2016
26
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
27
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016
28
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )
2016
29
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2016
30
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
31
Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )
2016
32
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
33
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )
2016
34
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. ( 27852700 )
2016
35
Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. ( 25702309 )
2015
36
Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy. ( 27051789 )
2015
37
A tumor control probability model for anal squamous cell carcinoma. ( 26243680 )
2015
38
Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. ( 26287957 )
2015
39
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. ( 25810165 )
2015
40
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 24839133 )
2015
41
Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study. ( 27774311 )
2015
42
High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. ( 25702585 )
2015
43
Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. ( 26678214 )
2015
44
Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil? ( 25987898 )
2015
45
Prognostic value of human papillomavirus in anal squamous cell carcinoma. ( 25209946 )
2014
46
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. ( 24885554 )
2014
47
Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review. ( 26753381 )
2014
48
Anal squamous cell carcinoma: an evolution in disease and management. ( 25278699 )
2014
49
Atypical pelvic recurrence of anal squamous cell carcinoma: successful endoscopic ultrasound-guided fine-needle aspiration through the sigmoid colon. ( 24997718 )
2014
50
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection. ( 23893826 )
2013

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 AKT1 APC PIK3CA TP53
2
Show member pathways
12.82 AKT1 CDKN2A MLH1 TP53
3
Show member pathways
12.65 AKT1 CDKN2A PIK3CA TP53
4
Show member pathways
12.63 AKT1 APC CDKN2A MLH1 PIK3CA TP53
5
Show member pathways
12.56 AKT1 CDKN2A PIK3CA RASSF1 TP53
6
Show member pathways
12.54 AKT1 APC PIK3CA TP53
7
Show member pathways
12.47 AKT1 APC CDKN2A MLH1 PIK3CA TP53
8
Show member pathways
12.36 AKT1 PIK3CA TP53
9 12.35 CDKN2A MGMT MLH1 TP53
10
Show member pathways
12.33 AKT1 PIK3CA TP53
11
Show member pathways
12.33 AKT1 APC PIK3CA TP53
12 12.33 APC CDKN2A PIK3CA RASSF1 TP53
13
Show member pathways
12.32 AKT1 PIK3CA TP53
14 12.25 APC CDKN2A TP53
15 12.24 AKT1 APC CDKN2A PIK3CA TP53
16 12.22 AKT1 APC CDKN2A MLH1 PIK3CA RASSF1
17 12.17 AKT1 PIK3CA TP53
18 12.17 AKT1 PIK3CA TP53
19 12.17 CDKN2A PIK3CA TP53
20
Show member pathways
12.05 AKT1 PIK3CA TP53
21 12.04 AKT1 PIK3CA TP53
22 12.03 AKT1 APC MLH1 TP53
23
Show member pathways
12.01 AKT1 PIK3CA TP53
24 11.98 AKT1 CDKN2A PIK3CA TP53
25 11.97 AKT1 PIK3CA TP53
26 11.96 AKT1 APC PIK3CA
27 11.93 APC MLH1 TP53
28 11.93 AKT1 PIK3CA TP53
29
Show member pathways
11.9 AKT1 PIK3CA TP53
30
Show member pathways
11.89 AKT1 PIK3CA TP53
31 11.87 AKT1 PIK3CA TP53
32 11.85 AKT1 PIK3CA TP53
33 11.74 AKT1 PIK3CA TP53
34 11.72 AKT1 APC CDKN2A PIK3CA TP53
35 11.63 CDKN2A RASSF1 TP53
36
Show member pathways
11.62 AKT1 CDKN2A TP53
37 11.6 AKT1 APC CDKN2A MGMT TP53
38
Show member pathways
11.55 AKT1 PIK3CA TP53
39 11.54 AKT1 PIK3CA TP53
40 11.53 AKT1 PIK3CA TP53
41 11.47 AKT1 RASSF1 TP53
42 11.4 AKT1 APC PIK3CA TP53
43
Show member pathways
11.39 MGMT MLH1
44 11.39 AKT1 PIK3CA
45 11.38 AKT1 APC
46 11.37 AKT1 PIK3CA
47
Show member pathways
11.34 MLH1 TP53
48 11.3 APC TP53
49 11.26 AKT1 PIK3CA
50 11.25 AKT1 PIK3CA

GO Terms for Anal Squamous Cell Carcinoma

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.8 CDKN2A MLH1 RASSF1 TP53
2 positive regulation of apoptotic process GO:0043065 9.56 AKT1 APC CDKN2A TP53
3 execution phase of apoptosis GO:0097194 9.54 AKT1 APC
4 cellular response to ionizing radiation GO:0071479 9.52 MGMT TP53
5 phosphatidylinositol 3-kinase signaling GO:0014065 9.51 AKT1 PIK3CA
6 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.48 APC CDKN2A
7 apoptotic mitochondrial changes GO:0008637 9.46 AKT1 CDKN2A
8 negative regulation of macroautophagy GO:0016242 9.43 AKT1 PIK3CA
9 mammary gland epithelial cell differentiation GO:0060644 9.4 AKT1 MGMT
10 replicative senescence GO:0090399 9.37 CDKN2A TP53
11 cellular response to DNA damage stimulus GO:0006974 9.35 AKT1 APC MGMT MLH1 TP53
12 Ras protein signal transduction GO:0007265 9.33 CDKN2A RASSF1 TP53
13 anoikis GO:0043276 9.32 AKT1 PIK3CA
14 cell cycle arrest GO:0007050 8.92 APC CDKN2A RASSF1 TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.16 CDKN2A TP53
2 protein phosphatase 2A binding GO:0051721 8.96 AKT1 TP53
3 protein kinase binding GO:0019901 8.92 AKT1 APC CDKN2A TP53

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....